Ace Therapeutics, a preclinical contract research organization specializing in analgesic drug research, has announced comprehensive end-to-end solutions for pain therapeutic development. The company offers a full spectrum of validated in vivo pain models for drug testing and a complete suite of preclinical research capabilities to support pharmaceutical and biotechnology customers worldwide.
The company's preclinical analgesic drug development services cover every stage from early target discovery and mechanism verification to pharmacological validation and safety assessment. Rooted in scientific rigor and regulatory-compliant methodologies, Ace Therapeutics has built integrated in vitro and in vivo research platforms tailored to study various physiological pain mechanisms, evaluate compound efficacy, and conduct safety profiling for novel analgesic candidates.
A core strength of Ace Therapeutics lies in its extensive portfolio of standardized and customized in vivo pain models for drug testing, which span nearly all mainstream pain classifications. These validated animal models include migraine models established via trigeminal ganglion electrical stimulation and nitroglycerin induction, as well as multiple neuropathic pain models such as spinal nerve ligation, chronic constriction injury, and diabetic neuropathic pain models.
To complement its in vivo systems, Ace Therapeutics has developed systematic preclinical pain assessment services, including mechanical pain, thermal pain, chemical pain, cold pain, and electrical stimulation pain assessments using well-established methods like the Von Frey Filament Test, Hot Plate Test, and Formalin Test. Meanwhile, the in vitro neuropathic pain model development services leverage dorsal root ganglion cells, iPSC-derived sensory neurons, and various co-culture systems to explore pain-related cellular mechanisms, enhancing translational value.
Beyond model construction and efficacy testing, Ace Therapeutics' preclinical analgesic drug development services extend to target-based and modality-based drug discovery. These services support research targeting G-protein coupled receptors, cytokine networks, and various ion channels, delivering professional solutions for small-molecule analgesics, biologics including antibodies, recombinant proteins, peptides, cell therapies, and gene therapy candidates. The company also offers mechanism-driven research covering peripheral inflammatory pathways, central regulatory pathways, neuronal signaling pathways, and neuro-immune interaction pathways.
The full-service pipeline also includes target validation, in vitro screening, in vivo pharmacology research, pharmacokinetics analysis, safety pharmacology, preclinical formulation development, and biomarker discovery. Professional PK/PD modeling, toxicity assessment, and formulation optimization help clients reduce research risks, determine optimal dosages, and accelerate candidate selection. For special research needs, Ace Therapeutics can design customized pain models and testing assays according to unique drug mechanisms and research objectives.
This announcement underscores the growing importance of specialized preclinical services in pain research, as the need for effective analgesics continues to rise. By providing a comprehensive platform, Ace Therapeutics aims to streamline the development of novel pain therapies, potentially addressing unmet medical needs in pain management.
